Position: CEO and President since 2021. Employed since 2021.

Education: BSc in business administration and economics from Örebro University.

Experience: Former experience in the pharmaceutical industry includes CEO at Sedana Medical Group (2017-2021) and CEO at Unimedic Group (2010-2016), CEO at Eisai AB (2005-2010) and additional more than 10 years of experience in leading positions in sales and marketing at AstraZeneca (including launch of Nexium), Meda and Wyeth.

Other assignments: Board member in FrostPharma AB, Prooxpharma AB, PMD Device Solutions AB and Waxholm by the sea AB.

Position: CSO since 2021. CEO between 2014-2021. Employed since 2014.

Education: BSc University of Gothenburg, PhD in Pharmacology University of Lund.

Experience: 30 years’ of experience from Astra/AstraZeneca. Preclinical project leader for Losec, the first PPI (Proton Pump Inhibitor) on the market. Preclinical project leader for Nexium including clinical, marketing and regulatory support. Discovery project leader on the P-CAB (Potassium-Competitive Acid Blocker) programme that brought linaprazan through the phase II clinical studies.

Other assignments: Board member in OBX Invest AB.

Position: CFO since 2021. Employed since 2021.

Education: BSc in Business Administration and Economics from Stockholm University.

Experience: Former CFO of Sedana Medical Group (2017-2021) and Managing Director at Cross Pharma AB (2015-2016). Maria has also extensive experience from leading positions within finance for the past 20 years within Medivir, Biovitrum, Bristol Myers Squibb and Ericsson.

Other assignments: Board Member in FAYSIT – Finance At Your Service In Tyresö AB and Advisory board member in Ugglapraktiken AB.

Position: COO since 2021. Employed since 2021.

Education: PhD in Cell-and Molecular Biology University of Lund, Sweden.

Experience: Former experience in the pharmaceutical industry includes CEO, COO and Clinical Advisor at SDS Life Science (2017-2021), Clinical- and Global Project Manager and Scientist in different positions at AstraZeneca R&D (2001 -2012). More than 20 years of experience from drug development and project management.

Position: CMO since 2022. Employed since 2022.

Education: MD and PhD in Medical Sciences, Karolinska Institutet, Stockholm, Sweden.

Experience: Consultant in Internal Medicine and Hematology/Hematooncology with more than 15 years’ of Clinical experience. From 2009 full time in the Pharmaceutical Industry at different positions within Medical Affairs and Clinical Development at national, regional and global levels in Genzyme, Roche, Alexion, Alnylam and Oncopeptides.

Position: Board member since 2014

Education: MD. Ph.D. Gastroenterologist and Internal Medicine and Hepatology from Karolinska Institutet, Stockholm, Sweden.

Experience: 27 years of Clinical experience. Consultant at AstraZeneca and former VP at Novartis. Developed the first modern H. pylori eradication therapy principles.

Other assignments: Member of the Board of PetoMaj Invest AB.

Position: Commercial Director since 2022. Consultant since 2022.

Education: BSc, Biochemistry, Molecular Biology, Microbiology from Sydney University, Australia and Master Commerce, Marketing and Finance, University of NSW, Australia.

Experience: Extensive experience from the pharmaceutical industry. Former Head Digital Transformation, at Novartis and Ass. Global Brand Director Diabetes at Novartis. Several executive positions within AstraZeneca such as VP Nexium, Global Marketing and Development, Global Product Director and Marketing Director Gastroenterology Nexium and Losec.

Other assignments: Board Member in PCW Consulting AB.